GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Operating Margin %

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Operating Margin % : 0.00% (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Forma Therapeutics Holdings's Operating Income for the three months ended in Jun. 2022 was $-53.00 Mil. Forma Therapeutics Holdings's Revenue for the three months ended in Jun. 2022 was $0.00 Mil. Therefore, Forma Therapeutics Holdings's Operating Margin % for the quarter that ended in Jun. 2022 was 0.00%.

The historical rank and industry rank for Forma Therapeutics Holdings's Operating Margin % or its related term are showing as below:


FMTX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -171.86
* Ranked among companies with meaningful Operating Margin % only.

Forma Therapeutics Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Forma Therapeutics Holdings's Operating Income for the three months ended in Jun. 2022 was $-53.00 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2022 was $-191.13 Mil.


Forma Therapeutics Holdings Operating Margin % Historical Data

The historical data trend for Forma Therapeutics Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Operating Margin % Chart

Forma Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Operating Margin %
5.91 -34.97 - -

Forma Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Forma Therapeutics Holdings's Operating Margin %

For the Biotechnology subindustry, Forma Therapeutics Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forma Therapeutics Holdings's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's Operating Margin % falls into.



Forma Therapeutics Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Forma Therapeutics Holdings's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-173.986 / 0
= %

Forma Therapeutics Holdings's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-52.998 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forma Therapeutics Holdings  (NAS:FMTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Forma Therapeutics Holdings Operating Margin % Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Executives
Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook officer: SVP, Chief Scientific Officer
Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans director
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023

EDBI Pte Ltd Buys 4, Sells 1 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-30-2023